|
1
|
Parkin DM, Bray F, Ferlay J, et al:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
van der Veldt AA, Haanen JB, van den
Eertwegh AJ, et al: Targeted therapy for renal cell cancer: current
perspectives. Discov Med. 10:394–405. 2010.PubMed/NCBI
|
|
3
|
Linehan WM, Zbar B, Bates SE, et al:
Cancer of the kidney and ureter. Cancer: Principles and Practice of
Oncology. 6th edition. DeVita VT Jr, Hellman S and Rosenberg SA:
Lippincott Williams & Wilkins; Philadelphia: pp. 1362–1396.
2001
|
|
4
|
Powles T, Chowdury S, Jones R, et al:
Sunitinib and other targeted therapies for renal cell carcinoma. Br
J Cancer. 104:741–745. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Motzer RJ, Hutson TE, Tomczak P, et al:
Sunitinib versus interferon alfa in metastatic renal-cell
carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Motzer RJ, Escudier B, Oudard S, et al:
Efficacy of everolimus in advanced renal cell carcinoma: a
double-blind, randomised, placebo-controlled phase III trial.
Lancet. 372:449–456. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Motzer RJ, Escudier B, Oudard S, et al:
Phase 3 trial of everolimus for metastatic renal cell carcinoma.
Cancer. 116:4256–4265. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Verheul HM and Pinedo HM: Possible
molecular mechanisms involved in the toxicity of angiogenesis
inhibition. Nat Rev Cancer. 7:475–485. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Padhy BM, Shanmugam SP, Gupta YK, et al:
Reversible posterior leucoencephalopathy syndrome in an elderly
male on sunitinib therapy. Br J Clin Pharmacol. 71:777–779. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Choueiri TK, Plantade A, Elson P, et al:
Efficacy of sunitinib and sorafenib in metastatic papillary and
chromophobe renal cell carcinoma. J Clin Oncol. 26:127–131. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hinchey J, Chaves C, Appignani B, et al: A
reversible posterior leukoencephalopathy syndrome. N Engl J Med.
334:494–500. 1996. View Article : Google Scholar
|
|
12
|
Martín G, Bellido L and Cruz JJ:
Reversible posterior leukoencephalopathy syndrome induced by
sunitinib. J Clin Oncol. 25:35592007.
|
|
13
|
Medioni J, Cojocarasu O, Banu E, et al:
Reversible encephalopathy syndrome secondary to sunitinib for
metastatic renal cell carcinoma patient. Targ Oncol. 2:193–195.
2007. View Article : Google Scholar
|
|
14
|
Cumurciuc R, Martinez-Almoyna L, Henry C,
et al: Posterior reversible encephalopathy syndrome during
sunitinib therapy. Rev Neurol (Paris). 164:605–607. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen A and Agarwal N: Reversible posterior
leucoencephalo-pathy syndrome associated with sunitinib. Intern Med
J. 39:341–342. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kapiteijn E, Brand A, Kroep J, et al:
Sunitinib induced hypertension, thrombotic microangiopathy and
reversible posterior leukencephalopathy syndrome. Ann Oncol.
18:1745–1747. 2007. View Article : Google Scholar
|
|
17
|
Fugate JE, Claassen DO, Cloft HJ, et al:
Posterior reversible encephalopathy syndrome: associated clinical
and radiologic findings. Mayo Clin Proc. 85:427–432. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Govindarajan R, Adusumilli J, Baxter DL,
et al: Reversible posterior leukencephalopathy syndrome induced by
RAF kinase inhibitor BAY 43–9006. J Clin Oncol.
24:e482006.PubMed/NCBI
|
|
19
|
Glusker P, Recht L and Lane B: Reversible
posterior leukoencephalopathy syndrome and bevacizumab. N Engl J
Med. 354:980–981. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ozcan C, Wong SJ and Hari P: Reversible
posterior leukencephalopathy syndrome and bevacizumab. N Engl J
Med. 354:981–982. 2006.
|
|
21
|
Paulson OB, Strandgaard S and Edvinsson L:
Cerebral autoregulation. Cerebrovasc Brain Metab Rev. 2:161–192.
1990.
|
|
22
|
Covarrubias DJ, Luetmer PH and Campeau NG:
Posterior reversible encephalopathy syndrome: prognostic utility of
quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol.
23:1038–1048. 2002.
|
|
23
|
Ito Y, Arahata Y, Goto Y, et al: Cisplatin
neurotoxicity presenting as reversible posterior
leukoencephalopathy syndrome. AJNR Am J Neuroradiol. 19:415–417.
1998.PubMed/NCBI
|
|
24
|
Agarwala SS and Case S: Everolimus
(RAD001) in the treatment of advanced renal cell carcinoma: a
review. Oncologist. 15:236–245. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schwartz RB: A reversible posterior
leukencephalopathy syndrome. N Engl J Med. 334:17431996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Weingarten K, Barbut D, Fillipi C, et al:
Acute hypertensive encephalopathy: findings on spin-echo and
gradient-echo MR-imaging. Am J Roentgenol. 162:665–670. 1994.
View Article : Google Scholar : PubMed/NCBI
|
